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Abstract

TRANSFORMING GROWTH FACTOR-P1 (TGF-PI)
INDUCES MAST CELL APOPTOSIS
By Farnaz Norozian
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2006

Major Director: John J. Ryan, Ph.D., Associate Professor

Mast cells are potent effectors of the inflammatory response, playing an important role in
atopy, bacterial immunity, and animal models of arthritis, multiple sclerosis, and heart
disease. Hence controlling mast cell numbers and responsiveness is essential for
preventing inflammatory disease. This work demonstrated that the cytokine TGF-P1 is a
potent inducer of mast cell apoptosis, a finding that was consistent for cultured mouse bone
marrow-derived mast cells, peritoneal mast cells, and human mast cells. Cell death
appeared to be the result of TGF-mediated repression of IL-3 receptor expression and
function, leading to mitochondria1 damage and activation of an apoptotic cascade acting

vii
via p53 and caspases. While IL-3 receptor expression was reduced within one day of TGFpl stimulation, apoptosis required at least 3 days to occur. This delay in onset is
postulated to allow for protective mast cell effector functions, protecting the host from
infection while preventing the establishment of chronic inflammation. These studies
support the theory that TGF-P 1 is an inhibitor of mast cell survival. Because of the
widespread expression of TGF-PI ,this cytokine may be an ideal candidate for control of
mast cell homeostasis.

Introduction
Mast cells are among the key players involved in defense mechanisms against
pathogens and signal the initial activities involved in immunity, such as inflammation, that
generate a vascular reaction and late phase activities that promote leukocyte accumulation
and ultimately wound healing (Groneberg et al., 2005). Mast cells are also critical effector
cells in immediate hypersensitivity, observed as a direct result of the various mediators
synthesized and secreted by the mast cells (Mekori and Metcalfe, 2000; Williams and
Galli, 2000). Mast cell activation results in the release of pre-formed vasoactive m i n e s
and de-novo synthesized cytokines, chemokines and prostaglandins that collectively
induce a local or systemic inflammatory response (Rivera, 2002). The effects that mast
cells have on the body can be traced back to the release of effector molecules stored in
granules that are exocytosed upon mast cell activation. Mast cell granules contain a
spectrum of molecules such as histamine, which can trigger allergy (Xie and He, 2005;
Falus and Meretey, 1992). Mast cells can also be stimulated to synthesize other cytokines
and chemokines that have chemotactic effects.
While mast cells are responsible for immediate hypersensitivity, their widespread
distribution in the skin and in the respiratory tract suggests a role for these cells as a firstline of defense against invading pathogens, and they have been found to be critical for host
resistance to some bacterial infections (Malaviya et al., 1995). Despite this protective role,
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unregulated mast cell activation can result in deleterious effects. In fact mast cells are
associated with human allergic disease and implicated in mouse models of the autoimmune
diseases such as multiple sclerosis and rheumatoid arthritis (Brown et al., 2002). Changes
in mast cell numbers and immunoregulatory effects have been observed in patients
presenting with symptoms ranging from simple cutaneous pruritis, urticaria and skin
lesions to severe nausea, vomiting, and tachycardia, as well as patients presenting with
delayed hypersensitivity, parasitic or bacterial infections, fibrosis, autoimmune diseases,
neoplasia, hyperplasia-induced mastocytosis, rheumatoid arthritis, and inflammatory bowel
disease (Ali and Panettieri, 2005; Kanamaru et al., 2005; Xie and He, 2005; Brandt E.B. et
al., 2003; Rice et al., 1998; Baram et al., 1997). The immunoregulatory effects of mast
cells can even be observed in patients with biomaterial implants, where mast cells and their
granular products, especially histamine, have been observed to be important in recruitment
of inflammatory cells as a response by .the host to biomaterial implants (Tang et al., 1998).
This evidence collectively supports the importance of understanding mast cell function in
the immune system.
Among the molecules produced by mast cells, many can act in an autocrine
manner. Molecules produced by other cells in the environment can affect mast cells in a
paracrine fashion (Kitaura et al., 2005). Transforming Growth Factor-beta 1 (TGF-PI) is
one such cytokine that is both produced by mast cells and is also available to the mast cell
in blood plasma. Our lab recently showed that TGF-Pl inhibits mast cell development and
dampens expression and function of mast cell IgE receptors (Kashyap et al, 2005; Gomez

et al., 2005). Many signaling pathways function to inhibit cell division, survival, and
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proliferation. TGF-beta is perhaps the best known example of a cytokine-mediated
pathway by which proliferation is inhibited (Edlund et al., 2003). These studies raise the
possibility that TGF-Dl is a paracrine or autocrine inhibitor of mast cell function.

Transforming Growth Factor-beta
The transforming growth factor-beta (TGF-P) superfamily consists of a large
number of structurally related, secreted, dimeric proteins. They act either as hormones, or
as local mediators to regulate a wide range of biological functions in all animals. TGF-P
function begins in development, where it regulates pattern initiation of embryo,
extracellular matrix production, and cell death. In adult life TGF-P functions in tissue
repair as well as in immune regulation. The TGF-P family consists of the TGF-Dl,-2,-3, as
well as activins, and bone morphogenetic proteins (BMPs) (ten Dijke and Hill, 2004; Shi
and Massague, 2003; Massague, 1990). TGF-P family proteins have both stimulatory and
inhibitory effects on a variety of cellular functions, including differentiation, proliferation,
and apoptosis. A number of studies have implicated TGF-P family members in several
different physiological processes including inflammation, fibrosis, and angiogenesis. TGF-

p proteins have also been linked to autoimmune disease, antherosclerosis, fibrotic disease,
and cancer in humans (Blobe et al., 2000; Letterio and Roberts, 1998).
All TGF-P proteins act through enzyme-linked receptors, transmembrane proteins
that span the membrane once, with a serinelthereonine kinase domain on the cytosolic side
of the plasma membrane (Benning, and Kyprianou, 2002). There are two types of
receptors, type I and type 11, and each member of the TGF-beta family binds to a specific
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combination of the receptors where both are required for .the proper signal transduction.
The most common scenario is that the ligand binds to the type 11 receptor, which forms
homodimers, recruiting, phosphorylating, and activating the type1 receptor homodimer
ultimately yielding an activated tetrameric receptor complex. The post tetrarneric receptor
complex signal is rapidly relayed to the nucleus by way of binding to and phosphorylating
Smad, a latent gene regulatory protein (Benning and Kyprianou, 2002). Dependent on the
actual ligand, either Smadl, 2, 3, 5, or 8 is activated. Once the specific Smad is
phosphorylated, it disassociates and binds to Smad4. This newly activated Smad4 forms a
complex with either Smadl, 2 , 3 , 5 or 8 and moves into the nucleus, where it associates
with other gene regulatory proteins, binds to specific target sites on the DNA, and activates
a particular set of target genes.
TGF-PI, the prototypic family member and the cytokine of interest for this study, is
synthesized as a precursor polypeptide and secreted in a latent form by most cell types (ten
Dijke and Hill, 2004; Shi and Massague, 2003; Massague, 1990). Studies showing the
inhibitory effects of TGF-PI on immune cell function support the role of TGF-Dl as a
suppressor of immunity and inflammation (reviewed in Letterio and Roberts, 1998).
Emphasizing the importance of TGF-Pl -mediated immunosuppression is the observation
that TGF-Dl -null mice develop severe inflammation, wasting syndrome, and organ failure
leading to death by 3 weeks of age (Kulkarni et al., 1993; Shull et al., 1992).
It is consistently evident that a key strategy of multicellular control is to balance
cellular growth and proliferation with cellular death. Therefore when mutations occur in
genes that regulate apoptosis, there is an increase in net cell numbers, a key hallmark of
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malignant cells (Edlund et al., 2003; Greenlee et al., 2000). Furthermore it has been shown
that disrupting the genes with products regulating cellular growth, proliferation and or
apoptosis, such as TGF-PI, can lead to excessive inflammatory responses (Kulkarni et al.,
1993). Such a mutation in TGF-P, its receptors, or any of the components of the pathway
by which it signals a cell to undergo apoptosis could result in tumor cell development,
fibrosis, angiogenesis, and range of autoimmune diseases listed above.
The term apoptosis, also known as programmed cell death or cellular suicide,
comes from the Greek word for "falling off," as in leaves from a tree, suggesting a natural
event in the life of living things. Apoptosis was first defined by J.F.R. Kerr in 1972 as a
systematic sequence of structural changes that a cell undergoes to ultiniately achieve
programmed cell death (Kerr et al., 1972). The cells of multicellular organisms are not
only highly organized but also strictly regulated. Cellular regulation via apoptosis is not
only a mechanism controlling when a cell needs to undergo programmed cell death, but
also the rate at which the process occurs.
Under normal conditions in a eukaryotic cell, there is an astonishing amount of
apoptosis that occurs in both developing and adult animal tissues. For example, during
embryonic development, cells undergo apoptosis when they are no longer needed such as
the webbing between fingers. Apoptosis also occurs in adults as billions of cells can
undergo apoptosis every hour in the bone marrow. This rate of cell death is balanced by
the division of cells with in the tissue (Tomei and Cope, 1991). Of course the above
examples are a mere glimpse into the world of cellular regulation via apoptosis. The role
of apoptosis may vary from tissue to tissue and cell-to-cell, however, the molecular
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mechanisms of apoptosis and its control described below share common themes. These
also work co-ordinately among various systems with cell proliferation to regulate cell
numbers in the multicellular world.

Intracellular & Extracellular System of Apoptosis
Apoptosis is a critical component of cellular regulation in normal cells. It is then
fitting that apoptosis is a well organized process with many intricate pathways still being
studied and elaborated. Generally when a cell undergoes apoptosis, it shrinks and the
chromatin condenses. The cytoskeleton collapses, the nuclear envelope disassembles, and
the nuclear DNA breaks up into fragments. The cell surface displays properties allowing it
to be recognized by target cells, which serve as signals for the apoptotic cell to be
phagocytosed rapidly. The common intercellular machinery responsible for apoptosis
seems to be similar across all animal cellular systems (Wyllie et al. 1990; Kerr et al. 1972).
The caspases are proteins with a key role in apoptotic pathways. Caspases are a
family of proteases with a cysteine in their active site and cleave their target proteins at
specific aspartic acids. They are synthesized in the cell as inactive precursors and are
activated upon proteolytic cleavage. Ultimately amplification of a proteolytic cascade
results in the cleavage of other key proteins such as the nuclear lamin, or a DNA-degrading
enzyme. This protease cascade is not only destructive and self-amplifying but also
irreversible (Wyllie et al. 1990).
These procaspase activations can be triggered from either the outside or inside of
the cell, for example, through killer lymphocytes, or via the mitochondria1 pathway by
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cytochrome C release, respectively. There are extracellular survival factors that suppress
apoptosis. These function in cellular growth control. When these survival factors are
removed the cell activates its programmed cell death mechanisms. A key player in the
mechanism by which a cell's survival is controlled is the state of the cell surface receptor
expression. A given ligand requires a functional receptor and functional pathwayassociated proteins to signal a cell to survive or undergo apoptosis.
Thus far the mechanisms explained by which extracellular factors control a
multicellular organism have been positive regulators. There are equally important
inhibitory extracellular signal proteins that oppose the positive regulators and thereby
inhibit proliferation. One of the best understood inhibitory signal proteins belongs to the
TGF-P family. TGF-P is known to stimulate apoptosis as well as inhibit the proliferation
of all most all cell types, with the one exception being fibroblasts.
TGF-PI is produced by mast cells and may be stored in their granules (Pennington
et al., 1991). TGF-PI is found in the cell matrix and kept in its latent form, which is

cleaved to the active form when needed (Lindstedt et al., 2001). TGF-PI can be observed
in circulating blood at concentrations exceeding 30 nglml (Young et al., 1999). In vivo
studies have shown that TGF-P 1 inhibits murine hypersensitivity (Meade et al. 1992).
However work done in the past in an attempt to elucidate the effect of TGF-p1 contradicts
the preliminary finding in our lab where TGF-beta has been observed to induce mast cell
death by apoptosis. Broide et al. (1989) reported that TGF-PI selectively inhibited IL-3
dependent proliferation of bone marrow-derived mast cells without affecting their overall
function or differentiation. However, the work reported by Broide et al. (1989) was
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performed using cellular proliferation assays administering TGF-Dl at a concentration of
0.1 nglml. In the same study cells were observed for only a short period of time, within 72
hours after TGF-PI treatment, and cell viability determined after trypan blue staining.
Although trypan blue is a useful, time efficient technique for determining viable cell
numbers, there are more sensitive techniques by which cellular proliferation, survival and
ultimately apoptosis can be measured. Furthermore, another study reported that TGF-Dl
prevents the Stem Cell Factor (SCF) rescue of IL-3 deprived IL-3-dependent mast cells.
SCF, the ligand for Kit, is known to rescue mast cells from an apoptotic fate (Mekori and
Metcalfe, 1994). This same study reported that no substantial effects were observed for
IL-3 dependent mast cells treated with TGF-PI. Perhaps these studies did not find the link
between TGF-PI and mast cell apoptosis however, they did find the inhibition of receptor
expression and or signaling that we suspect causes apoptosis. Inconsistencies between
studies presented in the past and the observations in our lab, provided an opportunity to
explore and elucidate the functions and immunoregulatory abilities of cytokines such as
TGF-P1 on mast cells. The objective of this study was to elucidate the effects of TGF-P1
on the survival of mast cells.

Experimental Designs and Methods
Cytokines and reagents
Murine IL-3, stem cell factor (SCF), and TGF-PI were purchased from R&D
System (Minneapolis, MN). Human SCF was the kind gift of Amgen Corp. Mouse IgE,
fluorescein isothiocyanate (F1TC)-conjugated rat anti-mouse Kit, phycoerythrin (PE)conjugated anti mouse IL-3RP, and PE-conjugated anti-human Kit were purchased from
BD PharMingen (San Diego, CA). FITC-conjugated rat anti-mouse IgE was purchased
from Southern Biotechnology Associates (Birmingham, AL). Stat5 antibodies were
purchased from Upstate Biotechnology (Lake Placid, NY).

Mouse bone marrow-derived mast cells (BMMC)
Bone marrow cells were obtained fiom C57BL16J female mice (3-5 weeks old)
(Jackson labs., Bar Harbor, ME) by with a 22 gauge needle, flushing femurs and tibias
containing complete RPMI media (RPMI 1640 medium (Life Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 Ulml
penicillin, 100 p/ml streptomycin, and 1 mM sodium pyruvate (all from Biofluids,
Rockville, MD). Red blood cells were removed with a ammonium chloride potassium
(ACK) lysis buffer. Cells were counted following trypan blue staining (trypan blue
solution, 0.4%, SIGMA, St. Louis, MO) and plated at 3 x lo5 cells/ml in cRPMI +
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Interleukin 3 (IL-3) + Stem Cell Factor (SCF) (30 nglml each) (Peprotech, Rocky Hill, NJ)
and incubated at 37°C for the duration of cultures (ThermoForma, Marietta, OH). Nonadherent cells were transferred to new plates every 4 days to select against adherent cells.
This ensured good recovery of mature mast cells after 2 1 days of culture.
After cells reached maturation, which was constituted by a population of >95%
with surface expression of Kit and TlIST2 and FccRI (data not shown), they were
maintained in 20% WEHI conditioned cRPM1. FccRI expression was monitored by with
mouse IgE (Pharmingen, San Diego, CA) and secondary staining with FITC-rat anti-mouse
IgE (Southern Biotechnology, Birmingham, AL). Antibody labeled data was acquired
with a BD-Pharmingn FACScan flow cytometer. BMMC were used within three months
of their maturation.
Peritoneal cells were harvested from euthanized mice by lavage of the peritoneum
with 5 ml of cRPMI injected into the peritoneal cavity. These cells were cultured in
cRPMI and IL-3+SCF. Human skin-derived mast cell populations, were derived as
described previously (Kepley, 2005) and provided by Dr. Kepley.

Culture conditions
Cells were plated at 3 x lo5 cells/ml in cRPMI. After 4 hours of starvation,
cytokines were added at the following final concentrations: IL-3 at 5 nglml; TGF-P1 at 5
nglml or 10 nglml as noted. Treatment conditions were as follows: treated with IL-3, IL-3

+ Vehicle, or IL-3 + TGF-PI . IL-3 and TGF-PI were purchased from R&D (Minneapolis,
MN). A solution of 4 mM HC1+ 1 mglml bovine serum albumin (BSA) was used as a
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vehicle to resuspend lyophilized TGF-PI. Cells were incubated at 37°C for indicated
times. Feeding of cultures was maintained every 4thday of culture, with half of the medium
and cytokines removed and replaced.

Mast cell viability and apoptosis
Cells were washed and re-plated at 3 x 1 0 ~cells/ml in 200 pl cRPMIIwel1 in 96-well
flat-bottom plates. IL-3 was added at 5 nglml, with indicated concentrations of TGF-PI.
Cultures were incubated for the indicated times. Every 4 days half the media and
cytokines were replaced. A volume of 200 p1 was harvested from culture conditions
described above, centrifuged in a 96-well v-bottom plate form 5 minutes and then washed
with PBS, twice. Cells were then fixed by resuspending in 150 p1 PI fixation buffer (35%
1X phosphate buffer solution (PBS), 52% EtOH, and 12.5% FCS), and stored at 4°C for 4
hrs-7 days. After fixation, cells were washed with PBS and resuspended in 200 p1 of PIDNA staining buffer (lml stock PI (1 mglml (SIGMA, St. Louis, MO)), 18.8 mls 1X PBS,
200 p1 of RNAse A (1 nglml (Boehringer Mannheim, Indianapolis, IN)), and 4 pl0.5 M
EDTA (Quality Biological Inc., Gaithersburg, MD)), incubated at room temperature in the
dark for2-3hrs. Cells were assessed for > diploid (viable) or sub-diploid (apoptotic) DNA
content by propidium iodide (PI) staining following cell fixation and permeabilization (PIDNA staining) by flow cytometry. Samples were analyzed by flow cytometry to
determine the percentage of the population in sub-diploid DNA state.
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Tissue culture conditionsfor cell viability and surface receptor expression
Cells were washed and re-plated at 3x10~cells/ml in 200 p1 cRPMIIwel1 in 96-well
flat-bottom plates. IL-3 was added at 5 nglml, with indicated concentrations of TGF-P1.
Cultures were incubated for the indicated times. Every 4 days half the media and
cytokines were replaced. Cells were harvested, and washed twice with FACS buffer (500
ml 1X PBS, 15 ml FBS, and 5 ml 10% Na Azide (SIGMA, St. Louis, MO), blocked with
an nonspecific binding antibody and then IL-3 Receptor-a, and IL-3 Receptor-P, and c-kit
Receptor expression was monitored with labeled or unlabeled antibodies for the receptors
(Purified IL-3R a ; PE anti-mouse PIL~IPc;PE anti-mouse CD117; respectively, BD
Bioscience, San Jose, CA), and data was acquired with a BD-Pharmingen FACScan flow
cytometer.

RNase Protection Assay (RPA):
Cells were cultured and treated by cytokines as previously indicated. To establish
whether the regulation of receptor expression was controlled at either the RNA level or at
the protein level, cells were cultured as described above and harvested at times before
apoptosis was observed with PI-DNA analysis. Whole cell RNA was isolated from 5 x lo6
cells, and mRNA expression of the receptors of interest or their subunits were checked by
RPA. RNA extraction was done with Trizol (Life Technologies, Gaithersburg, MD). The
Riboquant system kit (BD Pharmingen, San Diego, CA) was used to synthesize 3

2

(Uridine 5'-Triphosphate, [ a - 3 2 ~ IMP
] , Biomedicals, Aurora, OH) labeled probes
containing the IL-3 receptor

P mast cells gene and the control genes L32 and GAPDH,

~

-

~

~

~
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following the manufacturer's protocol. The expression of the genes of interest was then
determined with using polyacrylaminde gel electrophoresis. Results were visualized with
radiography, and quantitative analysis was obtained with phosphorimaging. The ratio of
the pixel intensity for each band of interest to the sum of the pixel intensities for the
housekeeping genes (L32+GAPDH) in that lane were determined. Calculations of percent
change in expression relative to control conditions were determined by comparing these
ratios.

Western blot analysis
Cells were cultured and treated by cytokines as previously indicated. Tyrosine
phosphorylated Stat5, total Stat5, and actin were detected by western blotting of total cell
lysates (approximately 50 pgllane). Anti-Stat 5 antibodies were purchased from Santa Cmz
Biotechnology (Santa Cruz, CA.). Cells were washed twice with WMI, replated at 5 x 1 0 ~
cellslml, incubated over night without IL-3, then restimulated with IL-3 at 100 nglml for
fifteen minutes. Cell lysates were harvested and protein levels analyzed by western blot.
To determine the percent change in expression, band intensity was measured by
densitometry. The ratio of tyrosine phosphorylated Stat5 to total Stat5 was determined,
and ratios were compared between lanes to determine percent decrease in the presence of
TGF-P1.

Caspase activation analysis:
Cells were cultured and treated by cytokines as previously indicated. Caspase
activation was assessed with the Caspatag assay (Intergen, Purchase, NY) specific for
caspase 3, 8, and 9 activation following the manufacturer's instructions.

Mitochondrial membrane potential analysis:
Cells were cultured and treated by cytokines as previously indicated. Cells were
harvested, washed twice with 1X PBS. A Di(OC& (3,3'-Dihexyloxacarbocyanine,iodide)
was added to 200 p1 of cells at a final concentration of 1 nM (Molecular Probes, Eugene,

OR). Cultures were incubated for 15 minutes at 37OC in a COz incubator. Cells
were washed twice with 1X PBS and resuspended in 200 pl PBS for flow cytometric
analysis. Mitochondrial membrane potential was observed, and data collected with the
BD-Pharmingen FACScan flow cytometer.

Results

TGF-PI induces mast cell apoptosis
To determine the effects of TGF on mast cell survival, mouse BMMC were
cultured with IL-3 +I- TGF-PI . BMMC are primary, IL-3 dependent mast cells that
function as a reliable model system for mucosal mast cells (Rottem et al., 1992), hence the
effects of TGF-P1 on this population are likely to be representative of connective tissue
mast cells. As shown in Figure 1A, BMMC cultured with TGF-P1 for 6 days exhibited an
increase in sub-diploid DNA content, indicating DNA fragmentation that is consistent with
apoptosis. Apoptosis occurred consistently after 3 days of culture, with a peak of 40-50%
cell death after 4 days of culture (Figure 1B). This effect was dose-dependent, requiring
approximately 2 nglml TGF-P 1, with maximum apoptosis observed at 10 nglml. As stated,
this is well with in the range of TGF-PI available in normal human serum (Young et al.,
1999).

TGF-PI-induced apoptosis correlates with reduced IL-3 receptor expression
TGF-P1 is known to block expression of the mast cell survival receptor Kit and
also inhibits Kit-mediated rescue from growth factor withdrawal-induced apoptosis (de
Vos et al., 1993; Dubois et al. 1994; Mekori and Metcalfe, 1994). Since IL-3 is the
survival factor used in these assays, loss of its survival function seemed a plausible means
15

by which TGF-P1 could elicit programmed cell death. To address this possibility, we
measured the effects of TGF-PI on BMMC IL-3 receptor expression with flow cytometry.
The IL-3R is composed of an alpha (a)chain paired with either an IL-3-specific beta (P)
chain or a common (PC)chain shared with IL-5 and GM-CSF (Kitamura and Miyajima,
1992). IL-3Ra expression was found to be below the level of detection (data not shown).
In contrast, an antibody that recognizes both IL-3RP chains demonstrated robust
expression that was significantly inhibited by TGF-PI (Figure 2A). Importantly, the
reduction of IL-3RP expression preceded the onset of cell death, with 30% inhibition after
8 hours of TGF-P1 stimulation, peaking at 65% inhibition by day 3 of culture, when
1

apoptosis was first detected (Figure 2B). Since BMMC die approximately 3 days after IL-

1

3 withdrawal (our unpublished findings), the timing of TGF-PI -mediated inhibition of IL-

i

3R expression fits well with the onset of apoptosis.
TGF-P1 was found to blocked mast cell FceRI expression by reducing translational
efficiency, with little effect on mRNA expression (Gomez et al., 2005). Like FceRI, we
found that TGF-PI had no effect on IL-3RP mRNA expression, and reduced PC message
by only 20% at time points preceding or after the onset of IL-3R repression (Figure 2C and
D). It appears that TGF-P1 most likely dampens IL-3R expression through posttranslational effects that occur with the appropriate timing to explain the onset of mast cell
apoptosis.
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TGF-Dl-mediated IL-3R repression inhibits Stat5 activation and maintenance of
mitochondrial membrane potential
If the reduction in IL-3R expression is functionally significant, it should prevent
proper activation of the Stat5 pathway, which we have shown to be essential for mast cell
survival (Shelburne et al., 2003). To test the effects of TGF-Pl on IL-3-mediated Stat5
signaling, BMMC were cultured in IL-3 +I- TGF-PI for 3 days, the point at which IL-3R
expression reached its nadir and apoptosis was initiated. After a starvation period to
remove any residual IL-3 signaling, these cells were re-stimulated with IL-3, and Stat5
phosphorylation was measured by western blotting. As shown in Figure 3A, TGF-P1
reduced Stat5 phosphorylation by 45-50%. Since we have found that Stat5 expression is
necessary for maintaining mitochondrial membrane potential (AYm) (Shelburne et al.,
2003), we determined the effect of TGF-P1 on AYm via Di(OC& staining. As shown in
Figure 3B, TGF-Pl -stimulated cells exhibited reduced Di(OC& staining, shifting toward
the spectrum displayed by BMMC cultured without IL-3, a condition known to induce
mitochondrial damage (Bojes et al., 1999). The results suggest that TGF-Pl -mediated
repression of the IL-3 receptor is biologically relevant, reducing IL-3 signaling to an extent
that induces mitochondria1 damage.

TGF-Dl-induced apoptosis requires p53 expression
Loss of IL-3 signaling has been shown to induce a p53-dependent apoptotic
cascade that occurs with mitochondrial damage (Blandino et al., 1995). The effects of
TGF-Pl mirror IL-3 deprivation, and hence may employ the p53 pathway for programmed
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cell death. In fact, we found that p53-deficient (KO) BMMC exhibited little apoptosis
after culture with TGF-PI (Figure 4A). This p53 dependency was confirmed by a
substantial reduction in TGF-Pl-mediated activation of effector caspases-3 and -7 (Figure
4B). These data support the theory that TGF-PI induces mast cell apoptosis by sufficiently
repressing IL-3 receptor expression to mimic IL-3 withdrawal and the p53dependentlmitochondrial pathway that ensues from this deprivation.
Factor-independent mastocytoma cells are resistant to TGF-Dl -induced apoptosis
If the effects of TGF-P1 are mediated via its blockade of the IL-3 receptor, cells not
requiring this growth factor should be resistant to TGF-PI. To test this, we cultured factorindependent P8 15 mastocytoma cells in IL-3 +/- TGF-PI . These cells possess a mutant,
constitutively active Kit receptor that drives their continual proliferation. As shown in
Figure 5A, TGF-P1 stimulation for 6 days had little effect on the viability of P8 15 cells.
We detected no significant change in sub-diploid DNA content and no increase in Caspase317 activation (Figure 5B). Thus these IL-3-independent mastocytoma cells are completely
resistant to TGF-Dl induced cell death, supporting our hypothesis that TGF-PI acts
through repression of IL-3R expression and signaling.

TGF-PI represses Kit expression and induces apoptosis in mouse peritoneal mast cells and
cultured human mast cells
While mouse BMMC are a reliable model system for studying mast cell biology,
their IL-3 dependency is distinct from the importance of SCF in vivo. To confirm that our
findings with BMMC cultures were consistent in other mast cell populations, we measure
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the effects of TGF-P1 on freshly isolated mouse peritoneal mast cells and cultured human
mast cells, which rely upon SCF for survival and proliferation signals. Peritoneal cells
were cultured for 6 days in IL-3 +SCF +/- TGF-PI. As shown in Figures 6A and ByTGFpl reduced the expression of both IL-3RP and SCF receptor, Kit, nearly 60%. Reduction
in number of mast cells in theses cultures was also observed at 80.5% (SD = 14.2, n = 6).
Human skin-derived mast cell populations (HSMC) also confirmed the inhibitory effects of
TGF-PI. By day 3 of culture in SCF+ TGF-PI, HSMC showed greatly reduced Kit
expression (Figure 6C). This effect mimicked our observation with the mouse IL-3R.
Further, TGF-Pl induced human mast cell apoptosis, as judged by the presence of subdiploid DNA (Figure 6D). These results were consistent in HSMC derived from 3
individuals, with apoptosis increasing from 18.2% to 36.1% after the addition of TGF-P1
(p = 0.02). Hence the apoptotic effects of TGF-Pl are consistent in murine and human
mast cells cultured ex vivo.

Discussion

Mast cell activation is a central facet of atopic diseases such as allergic asthma.
The incidence of these diseases has risen dramatically in recent years, emphasizing the
importance of understanding and controlling mast cell function. Our efforts have focused
on mast cell homeostasis, regulating cell numbers and function. Since mast cells provide
critical resistance to bacterial and parasitic infections, but also elicit inflammation related
atopy, arthritis, multiple sclerosis, and heart disease, this cellular homeostasis maybe the
fulcrum balancing health and disease. Mast cells are responsive to many cytokines that
can provide homeostatic control. It has been shown that the Th2 cytokines IL-4 an IL- 10
repress mast cell development, activation, and survival (Bouton et al., 2004; Gillespie et
al. ., 2004, Bailey et al., 2004; Yeatman et al., 2000; Mirmonsef et al., 1999; Ryan et al.,
1998). While Th2 cells are closely tied to mast cell activity, the presence of TGF-PI in
tissues where mast cells reside, and the high level of serum TGF-PI available during
inflammation-induced vasodilation drew our attention to this cytokine. In testing the
effects of TGF-P 1 on mast cells, we found it capable of suppressing mast cell development
and inhibiting IgE receptor expression and function (Gomez et al., 2005; Kashyap et
a1.,2005). It was during these experiments that we noted the apoptotic effect of TGF-P1.
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This work shows that TGF-P1 elicits mast cell apoptosis by repressing IL-3R
expression, resulting in a factor-withdrawal response occurring with p53 activation,
mitochondria1 damage and caspase activation. These effects were consistent in cultured
mouse mast cells, peritoneal mouse mast cells, and human mast cells. Thus it is unlikely
that our data are related to culture artifacts or species differences. This inhibitory signaling
was sensitive, occurring at 1-2 nglml, which is well below the physiological concentration
of TGF-P 1.
Our studies with TGF-P1 demonstrate its role as a potent inhibitor of mast cell,
supporting the hypothesis that it can contribute to mast cell homeostatsis. This theory is
bolstered by the work of several other labs. For example, TGF-P1 diminished IgEmediated histamine release of TNF alpha production in vitro (Bissonnette et al., 1997), and
inhibited in vivo mast cell responses (Meade et al., 1992). TGF-PI has been shown to
inhibit IL-3, IL-4, and SCF-mediated signaling of mast cells, decreasing proliferation or
rescue from apoptosis (Toyota et al., 1995; Mekori and Metcalfe, 1994; Broide et al.,
1989).
The timing of TGF-PI -mediated inhibitory effects mirrors very much the work of
this lab with IL-4 and IL-10, which diminishes mast cell function and survival after 3-6
days of culture (Bouton et al., 2004; Gillespie et al. ., 2004, Bailey et al., 2004; Yeatman et
al., 2000; Mirmonsef et al., 1999; Ryan et al., 1998). We have postulated that this delay in
inhibitory signaling may frame an "inflammatory window" during which mast cell
responses elicit inflammation to control infection, but after which mast cells are repressed
to prevent tissue damage. The effects of TGF-PI fit well with this theory. For example,
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TGF-P1 has been reported to elicit mast cell migration (Olsson et al., 2001; Olsson et al.,
2000). There is also evidence that mast cell proteases activate latent TGF-P1 (Lindstedt et
al, 2001; Taipale et al., 1995). Thus it is plausible that TGF-P1 acts to draw mast cells to
an area of inflammation, where they serve a protective role. Subsequent to prolonged (3
day) stimulation with TGF-PI, in part mediated by latent TGF-P1 activation by mast cell
proteases, mast cell function and survival would be repressed. This feedback system
would restore homeostasis and prevent chronic inflammatory disease.
This is the first evidence that TGF-P1 directly induces apoptosis of mouse and
human mast cells. Our results support the concept that TGF-P1 and other inhibitory
cytokines normally function in a homeostatic fashion controlling the mast cell
inflammatory response. It is plausible that loss of these control mechanisms contributes to
inflammatory and autoimmune diseases, emphasizing the importance of understanding the
molecular mechanisms controlling mast cell homeostasis.
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Figure 1: TGF-P1 Induces Mast Cell Apoptosis

(A) The Effect of TGF-P1 on Murine Mast Cells. Mouse BMMC were cultured
for 6 days in IL-3 +I- 10 nglml TGF-pl. Apoptosis was measured by the
presence of sub-diploid DNA content after PI-DNA staining, as indicated by
marked region in histogram.

(B) The Effect of TGF-P1 Over Time. BMMC were cultured as in part (A) for the
indicated days, and apoptosis was measured by PI-DNA staining. Data shown
are means and standard errors from at least 6 sampleslpoint.

(C) The Effect of TGF-PI: A Dose Response. Concentration response for TGF-

p 1-induced apoptosis.

BMMC were cultured in 11-3 +I- the indicated

concentrations of TGF-PI for 7 days. Apoptosis was measure by PI-DNA
staining. Data shown are means and standard errors of 6 sampleslpoint.
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Figure 2: TGF-P1 Inhibits Mast Cell I L 3 R

(A) The Effect of TGF-$1 on I L 3 R p Expression. Mouse BMMC were cultured
for 3 days with IL-3 +I- TGF-P1 (10 nglml). Cells were analyzed for surface
IL-3RP expression via flow cytometry. Control stain was performed with PEcoupled IgG.

(B) The Effect of TGF-$1 on I L 3 R p Expression Over Time. Time course of
TGF-P 1-mediated inhibitory effects of IL-3RP expression. Cells were cultured
for the indicated times, and percent decrease in IL-3RP expression was
calculated by comparing mean fluorescence intensity of IL-3RP staining from
cells cultured +I- TGF-PI, as measured by flow cytometry. Data shown are
means and standard deviation of at least 3 sampleslpoint.

(C) RPA of I L 3 R P Chains. Effect of TGF-p1 on IL-3Rp mRNA expression.
RNase protection assay was used to measure IL-3RP mRNAs from BMMC
cultured for the indicated time +I- TGF-P 1.

(D) The Effect of TGF-$1 on I L 3 R p mRNA Expression Over Time. Summary
of TGF-P1 effects on IL-3RP mRNA expression. After normalizing to
L32+GAPDH loading controls, percent decrease in mRNA expression was
calculated as described in Materials and Methods. Data shown are means and
standard deviation of 3 sampleslpoint.
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Figure 3: TGF-$1 Inhibits IL3R Signaling.

(A)TGF-$1 on Stat5 and p-STAT5 Expression Over Time. BMMC were
cultured for 3 days in IL-3 +I- TGF-P 1, washed and incubated overnight in the
same medium lacking IL-3, then restimulated with IL-3 (100 nglml) for 15
minutes. Total cell lysates were subjected to western blot analysis with
phosphotyrosine-specific (pY) anti-Stat5. Membrane was stripped and reprobed with anti-Stat5 and anti-actin. After normalizing to Stat5 expression via
densitometry, pY-Stat5 expression was found to be reduced by 44.6% in
samples receiving TGF-P1 . Similar results were found in two experiments.

(B) AYm of Mast Cells Treated With TGF-PI. BMMC were cultured for 4 days
in IL-3 +I- TGF-PI or in media lacking cytokines. Di(OC& staining was used
to measure changes in AYm, as detected by flow cytometry. Numbers in
parentheses indicate the percentage of each population demonstrating reduced
AYm.
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Figure 4: TGF-Dl-mediated Apoptosis Proceeds Via The Mitochondrion and p53

(A)The Effect of TGF-P1 on p53KO Survival. Wild type (WT) and p53deficient (KO) BMMC were cultured in IL-3 +I- TGF-Pl for 6 days, and
apoptosis was measured by PI-DNA staining. Data shown are means and
standard errors of at least 9 sampleslpoint. *p < 0.001 by Student's t test.

(B) The Effect of TGF-P1 on WT and p53 KO Mast Cell Caspase 317 Activity.
Effects of TGF-Pl on caspase 317 activation in WT and p53 KO BMMC. Cells
were cultured for 6 days in IL-3 +I- TGF-PI, and caspase activation was
measured by flow cytometry as described in Materials and Methods.
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Figure 5: Effect of TGF-P1 On Mastocytoma Cells.

(A) % Apoptosis of WT vs Mastocytoma Mast Cells Treated With TGF-PI.

BMMC and P8 15 mastocytoma cells were cultured in IL-3 +I- TGF-P 1 for 6
days. Apoptosis was measured by PI-DNA staining. Percentage of the
population demonstrating sub-diploid DNA content is indicated.

(B The Effect of TGF-P1 on WT vs Mastocytoma Mast Cell Caspase 317
Activity. BMMC and P815 mastocytoma cells were cultured in IL-3 +I- TGF-

p l for 6 days. Caspase 317 activation was measured by flow cytometry.

Percentage of each population with active caspase is indicated.
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Figure 6: Effects of TGF-P1 On Mouse Peritoneal and Human Mast Cells.

(A)The Effect of TGF-P1 on Mouse Peritoneal Mast Cell Kit Expression.
Mouse peritoneal cells were cultured in IL-3+SCF +I- TGF-P 1 for 6 days,
followed by flow cytometric analysis with anti-Kit and anti-IL-3RP. Dot plot
is a representative 1 of 6 sample sets.

(B) Percent Inhibiton of Mouse Peritoneal Mast Cell I L 3 R P and Kit
Expression After Treatment with TGF-Dl. Mouse peritoneal cells were
cultured in IL-3+SCF +I-TGF-Pl for 6 days, followed by flow cytometric
analysis with anit-Kit and anti-IL-3RP. The average decrease in Kit and IL-3RP
expression +I- SD shown.
(C)The Effect of TGF-P1 on Human Mast Cell Kit Expression. Skin-derived
human mast cells were cultured in SCF +I- TGF-PI. On day 3, surface Kit
expression was measured by flow cytometry.

(D) The Effect of TGF-P1 on Human Mast Cell Survival. Apoptosis was
measured in cultures described in part (C) on day 7, by PI-DNA staining. Data
shown are representative of 3 independent mast cell cultures that yield similar
results.
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